Charles River wins gene therapy manufacturing contract from Nanoscope

By Nick Taylor

- Last updated on GMT

© chemicalbilly / Getty Images
© chemicalbilly / Getty Images

Related tags Charles river Charles river laboratories Gene therapy

Charles River Laboratories’ growing gene therapy manufacturing capabilities have landed it a deal with the eye disease biotech Nanoscope Therapeutics.

Nanoscope is advancing a pipeline of gene therapies against retinal degenerative diseases that is led by a treatment for retinitis pigmentosa (RP). With a Phase 2b/3 clinical trial of the RP candidate scheduled to post data early next year, the biotech has partnered with Charles River to access contract development and manufacturing services.

We are excited to continue to support Nanoscope Therapeutics’ efforts in the production of gene therapies that are focused on restoring vision for people suffering from retinal degenerative diseases with no known cure. Their work is incredibly important to patients, and we look forward to continuing to serve as a partner​,” said Kerstin Dolph, corporate senior vice president, biologics solutions, Charles River.

Charles River will support Nanoscope with good manufacturing practice (GMP) cell banking, high quality and GMP-grade plasmid DNA manufacture, and GMP adeno-associated virus (AAV) production. Covering both plasmid DNA and viral vectors, the collaboration taps into the breadth of services that Charles River has built up recently and that Nanoscope will need to advance its AAV2 gene therapies.

Best known as a provider of preclinical services, Charles River made a play for the fast-growing cell therapy, viral vector, and plasmid DNA production markets last year by acquiring Cognate BioServices, Cobra Biologics, and Vigene Biosciences.

The service provider has used the acquired capabilities to establish an AAV vector platform designed to reduce the time from process development to GMP by 55% and to deliver a drug product in fewer than eight months.

Charles River has also continued to add capacity since closing the deals, including by setting up a facility close to Cobra’s base in the UK. The new facility, which is located at the former AstraZeneca campus at Alderley Park, opened over the summer after a £7m ($8m) investment in new equipment.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more